JP2014141531A - Completion version of cancer eradication oral medicine - Google Patents
Completion version of cancer eradication oral medicine Download PDFInfo
- Publication number
- JP2014141531A JP2014141531A JP2014098205A JP2014098205A JP2014141531A JP 2014141531 A JP2014141531 A JP 2014141531A JP 2014098205 A JP2014098205 A JP 2014098205A JP 2014098205 A JP2014098205 A JP 2014098205A JP 2014141531 A JP2014141531 A JP 2014141531A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- mir
- oral medicine
- micrornas
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明は、ヒトiPSを介したがんの完治を目的とした治療薬に関する。 The present invention relates to a therapeutic agent aimed at complete cure of cancer via human iPS.
従来、ヒトiPSがん初期化の発見発明があったが全身がん細胞まで届ける技術はなかった。 Conventionally, there has been a discovery invention of human iPS cancer reprogramming, but there has been no technology for delivering systemic cancer cells.
従来、ヒトiPSがん初期化の発見発明があったが全身がん細胞まで届ける技術はなかったので最新技術よって改良実現させる。 Conventionally, there has been a discovery invention for human iPS cancer reprogramming, but there has been no technology for delivering systemic cancer cells, so improvements are realized by the latest technology.
ヒトiPS仲介がん細胞初期化するmiR-520dをカプセルに入れるかコーティングして経口で腸での消化吸収し血液成分として全身のがん細胞まで届ける。 Encapsulate or coat miR-520d, which initializes human iPS-mediated cancer cells, and digestively absorb in the intestine and deliver it to cancer cells throughout the body as a blood component.
全身がん細胞を正常細胞に初期化して治す。 Initialize and cure systemic cancer cells to normal cells.
以下、本発明の実施例について時系列的に文章で説明する。主としてヒトiPS仲介でがん細胞を初期化するのに必要なマイクロRNAの1つであるmiR-520dを用意し、これを胃酸や熱で壊れないようにコーティングするか、カプセルに入れ、従来、miR-520dを血液中に入れていたが、これを経口式にすることで口から飲むという単純化とし、このようにしてマイクロRNAの1つであるmiR-520dを腸で消化吸収し血液中の成分となり全身に血液に乗って行き渡り全身末期がんの全細胞が初期化し正常細胞に戻りで完成する、
以上のような特徴を持つ完成版がん根絶経口薬。
Hereinafter, embodiments of the present invention will be described in a chronological order in text. Prepare miR-520d, which is one of the microRNAs necessary for reprogramming cancer cells mainly mediated by human iPS, and either coat it with gastric acid or heat so that it does not break or encapsulate it. miR-520d was put in the blood, but by making it oral, it was simplified to drink from the mouth, and miR-520d, one of the microRNAs, was digested and absorbed in the intestine in this way. It becomes a component of and spreads on blood throughout the body, completes all cells of end-stage cancer and returns to normal cells to complete.
Completed cancer eradication oral medicine with the above characteristics.
上記の形態や非特許文献の如く実施される。 The present invention is implemented as in the above forms and non-patent documents.
従来、ヒトiPSがん初期化の発見発明があったが全身がん細胞まで届ける技術はなかったので最新技術よって改良実現させるため、ヒトiPS仲介がん細胞初期化するmiR-520dをカプセルに入れるかコーティングして経口で腸での消化吸収し血液成分として全身のがん細胞まで届ける。 がん薬の改良技術で大きく進歩を遂げがん患者数が多い中この薬の需要の産業上の利用可能性は高いと解される。
Previously, there was a discovery invention of human iPS cancer reprogramming, but there was no technology to reach whole body cancer cells, so miR-520d for human iPS-mediated cancer cell reprogramming is encapsulated in order to improve it with the latest technology Or it is coated and digested and absorbed in the intestine and delivered to cancer cells throughout the body as a blood component. While significant progress has been made in improving cancer drugs and the number of cancer patients is large, it is understood that the industrial applicability of this drug demand is high.
Claims (1)
(ロ)これを胃酸や熱で壊れないようにコーティングするか、カプセルに入れ、
(ハ)従来、miR-520dを血液中に入れていたが、これを経口式にすることで口から飲むという単純化とし、
(ニ)このようにしてマイクロRNAの1つであるmiR-520dを腸で消化吸収し血液中の成分となり全身に血液に乗って行き渡り全身末期がんの全細胞が初期化し正常細胞に戻りで完成する、
以上のような特徴を持つ完成版がん根絶経口薬。
(I) Prepare miR-520d, which is one of the microRNAs required to reprogram cancer cells mainly mediated by human iPS,
(B) Coat this so that it is not broken by stomach acid or heat, or put it in a capsule,
(C) Traditionally miR-520d was put in the blood, but by making it oral, it was simplified to drink from the mouth,
(D) In this way, miR-520d, one of the microRNAs, is digested and absorbed in the intestine, becomes a component in the blood, rides on the whole body and spreads throughout the body, and all cells of the end-stage cancer are initialized and returned to normal cells. Complete,
Completed cancer eradication oral medicine with the above characteristics.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014098205A JP2014141531A (en) | 2014-05-10 | 2014-05-10 | Completion version of cancer eradication oral medicine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014098205A JP2014141531A (en) | 2014-05-10 | 2014-05-10 | Completion version of cancer eradication oral medicine |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2014141531A true JP2014141531A (en) | 2014-08-07 |
Family
ID=51423108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014098205A Pending JP2014141531A (en) | 2014-05-10 | 2014-05-10 | Completion version of cancer eradication oral medicine |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2014141531A (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009535045A (en) * | 2006-05-04 | 2009-10-01 | ノバルティス アクチエンゲゼルシャフト | Small interfering ribonucleic acid (siRNA) for oral administration |
JP2010053078A (en) * | 2008-08-28 | 2010-03-11 | Teika Seiyaku Kk | Percutaneously absorbable pharmaceutical composition of oxycodone, pharmaceutical composition storage unit and percutaneously absorbable preparation by utilizing the same |
WO2012081531A1 (en) * | 2010-12-14 | 2012-06-21 | 新田ゼラチン株式会社 | Disease inhibiting agent |
JP2013147459A (en) * | 2012-01-19 | 2013-08-01 | Mikasa Seiyaku Co Ltd | Pruritus improvement percutaneous absorption plaster |
JP2013189451A (en) * | 2007-03-02 | 2013-09-26 | Teika Seiyaku Kk | Medicinal composition storing unit |
JP2014037358A (en) * | 2012-08-13 | 2014-02-27 | Osaka Univ | Oral formulation of nucleic acid medicine |
-
2014
- 2014-05-10 JP JP2014098205A patent/JP2014141531A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009535045A (en) * | 2006-05-04 | 2009-10-01 | ノバルティス アクチエンゲゼルシャフト | Small interfering ribonucleic acid (siRNA) for oral administration |
JP2013189451A (en) * | 2007-03-02 | 2013-09-26 | Teika Seiyaku Kk | Medicinal composition storing unit |
JP2010053078A (en) * | 2008-08-28 | 2010-03-11 | Teika Seiyaku Kk | Percutaneously absorbable pharmaceutical composition of oxycodone, pharmaceutical composition storage unit and percutaneously absorbable preparation by utilizing the same |
WO2012081531A1 (en) * | 2010-12-14 | 2012-06-21 | 新田ゼラチン株式会社 | Disease inhibiting agent |
JP2013147459A (en) * | 2012-01-19 | 2013-08-01 | Mikasa Seiyaku Co Ltd | Pruritus improvement percutaneous absorption plaster |
JP2014037358A (en) * | 2012-08-13 | 2014-02-27 | Osaka Univ | Oral formulation of nucleic acid medicine |
Non-Patent Citations (1)
Title |
---|
JPN6015016294; Scientific Reports, 2014.1, vol.4, No.3852, No.1-14 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR212016030926U2 (en) | target conjugates and particles and formulations thereof | |
WO2017091749A8 (en) | Shape changing drug delivery devices and methods | |
WO2016046793A3 (en) | Radiopharmaceutical conjugate of a metabolite and an epr agent, for targeting tumour cells | |
EA201401028A1 (en) | PHARMACEUTICAL COMPOSITION, CONTAINING EMAGOGLIFLOZIN AND MEDICINES FOR OBESITY | |
EP4233978A3 (en) | Oral delivery of active drug substances | |
EA201791702A1 (en) | THERAPEUTIC TOOLS ON THE BASIS OF GLYCANS AND RELATED METHODS | |
JP2011079858A5 (en) | ||
EA201491299A1 (en) | CARBAMATIC CONNECTIONS, THEIR PRODUCTION AND APPLICATION | |
EA201690207A1 (en) | TRADITIONAL CHINESE MEDICINE COMPOSITION AND DRUGS AND THEIR APPLICATION | |
JP2016532516A5 (en) | ||
MX367597B (en) | Silk-based capsules. | |
BR112017028552A2 (en) | particles and conjugates and formulations thereof | |
WO2016040462A3 (en) | Formulations and methods for treatment of metabolic syndrome | |
JP2014141531A (en) | Completion version of cancer eradication oral medicine | |
MX2017002897A (en) | Semi-solid chewable dosage form for over-the-counter medications and methods for producing same. | |
JP2015044878A5 (en) | ||
JP2014506563A5 (en) | ||
CN104547150A (en) | Application of inflammation-diminishing and pain-relieving external medicine as oral agent for treating tumors and ulcerative carbuncles | |
Fang et al. | Shall CRT-D be downgraded to CRT-P in super-responders of cardiac resynchronization therapy? | |
JP2016533856A5 (en) | ||
Sharma et al. | C58 EMERGING TECHNIQUES AND NEW TOOLS TO UNDERSTAND LUNG DISEASES: Lung Targeted Plga-Peg Nanocapsules Containing First Line Anti-Tubercular Drugs For Therapy Of Experimental Tuberculosis | |
PH12014502170A1 (en) | Drug composition and soft capsule drug sealing the drug composition | |
Menéndez et al. | Diagnosis and therapy of Hepatocarcinoma: update of the topic and the internist s role | |
CN103585217A (en) | Setose thistle/herba cephalanoploris pill | |
CN103585487A (en) | Reed rhizome/couch-grass root pill |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150512 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150519 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20151013 |